Selected article for: "million death and respiratory tract infection"

Author: Durigon, Edison Luiz; Botosso, Viviane Fongaro; de Oliveira, Danielle Bruna Leal
Title: Human Respiratory Syncytial Virus: Biology, Epidemiology, and Control
  • Cord-id: khvs2h55
  • Document date: 2017_6_21
  • ID: khvs2h55
    Snippet: According to the World Health Organization, acute lower respiratory tract infection (ALRI) is the fourth leading cause of death worldwide, responsible for approximately 3.1 million (5.5%) of the 56 million estimated deaths per year. Human respiratory syncytial virus (RSV) is recognized as the most important cause of ALRI in infants worldwide. It is estimated that every year 33.8 million new cases of RSV-related ALRIs occur and cause approximately 200,000 deaths in children younger than 5 years;
    Document: According to the World Health Organization, acute lower respiratory tract infection (ALRI) is the fourth leading cause of death worldwide, responsible for approximately 3.1 million (5.5%) of the 56 million estimated deaths per year. Human respiratory syncytial virus (RSV) is recognized as the most important cause of ALRI in infants worldwide. It is estimated that every year 33.8 million new cases of RSV-related ALRIs occur and cause approximately 200,000 deaths in children younger than 5 years; of note, 99% of these deaths occur in developing countries. Usually primary infections occur during the first 2 years of life and are symptomatic, causing from mild upper respiratory tract illness to severe ALRI, and in some cases pneumonia and bronchiolitis may occur simultaneously. Recurrent infections throughout life are common but normally cause milder upper respiratory tract illness. Several studies also associated severe RSV infections during infancy with permanent lung function reduction in adulthood, with higher risk of asthma. The seasonality of the virus varies but it is often detected throughout the year. In South America the highest incidence occurs in the months of January to June. Despite the clinical importance and the disease burden associated with RSV, there is neither specific treatment nor vaccines widely accepted and available nowadays.

    Search related documents:
    Co phrase search for related documents
    • ability specificity and acute respiratory infection: 1
    • acute respiratory disease and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory disease and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory disease and liver cell: 1, 2, 3, 4
    • acute respiratory disease and long term protective immunity: 1
    • acute respiratory infection and additional study: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory infection and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory infection and live virus vaccine: 1
    • acute respiratory infection and liver cell: 1, 2, 3, 4
    • acute respiratory infection and long term protective immunity: 1
    • additional study and live virus: 1
    • additional study and live virus vaccine: 1
    • additional study and liver cell: 1